BioSig Technologies, Inc. (NASDAQ: BSGM) or (“BioSig” or "the
Company"), a medical technology company delivering unprecedented
accuracy and precision to intra-cardiac signal visualization, today
announced new appointments to its now fully constituted board of
directors (the “Board”), which is comprised of a total of five (5)
directors, three (3) of whom are classified as independent
directors. The final compositions of the committees to the Board
will be determined in the very near term.
Commenting on the newly assembled Board, BioSig’s CEO, Mr.
Anthony Amato stated, “The Company is proud to introduce its new
members on our Board, which includes talented individuals with
years of experience across a broad array of industries and
professions. The Board is now compliant with the rules and
regulations that govern the standards acceptable to major U.S.
Exchanges, including three (3) highly qualified independent
directors, and I am confident that our directors will uphold their
strategic, financial, and managerial responsibilities to the
Company. BioSig continues to realize important and meaningful
progress and is working with great urgency to create lasting
shareholder value.”
Board Member #1, Anthony Amato
Mr. Anthony Amato is a business leader and entrepreneurial
thinker with an intuitive ability to rapidly assess challenges and
identify growth opportunities. He quickly sees organizational
vision and understands goals, taking appropriate ownership and
action required to guide the team, achieving aggressive targets and
performance levels. Mr. Amato has hands-on executive skills at
engaging and influencing key stakeholders to not only grow business
but also to optimize profits.
Mr. Amato founded InQuest Science in March 2017 and then
acquired Bridge Associates International Pharmaceutical Consulting
in March 2020. He is the former director of Sales for Mesa Labs
(MLAB) in Denver CO, a Nasdaq listed corporation that specializes
in providing quality control products and services to ensure the
safety and efficacy of equipment used in hospitals, pharmaceutical,
medical device manufacturers, blood banks, laboratories,
pharmacies, and industrial facilities.
In July of 1999, Mr. Amato founded Amega Scientific Corporation.
He grew the company from a startup operation to a worldwide
industry leader.Mr. Amato developed and managed a staff with
multiple North American offices, establishing R&D, production,
logistics, administration, and sales. Clients included
pharmaceutical, biotech, hospitals, government facilities, and
research universities. Amega Scientific was a leading innovator for
the environmental monitoring system industry. Amega Scientific was
an ISO 17025 corporation instituting GXP requirements. Amega
Scientific was acquired by Mesa Labs in November 2013.
Mr. Amato graduated from Glassboro State College
in New Jersey in 1989, with a dual degree in business management
and finance. Mr. Amato’s outstanding interpersonal, business
development, team building, and management skills make him an asset
to the Company’s board of directors.
Board Member #2, Chris Baer
Mr. Chris Baer brings more than 25 years of commercial
experience in the medical device space across both large publicly
held and smaller privately held organizations. He currently serves
as the chief commercial officer at CDL Nuclear Technologies. He
started in this role in April 2022 and prior to that from June 2019
to April 2022 he served as the vice president of commercial
operations at Impulse Dynamics. He also held several commercial
leadership roles in the cardiac rhythm management and
electrophysiology space including vice president and general
manager at St. Jude Medical / Abbott. Mr. Baer holds a pharmacy
degree from The University of Pittsburgh. Mr. Baer’s extensive
experience in the electrophysiology medical device space makes him
a valuable member of our Board.
Director #3, Frederick D. Hrkac
Mr. Frederick D. Hrkac has more than 30 years of experience in
the medical device industry as an executive and corporate board
director. He is currently serves on the board of Serres in
Helsinki, Finland since September 2018, and Spineart in Geneva,
Switzerland as chairman of the board since August 2017. In 2017, he
served as senior vice president corporate development and from
2014-2016 served a senior vice president of global commercial
operations of Biosensors International. From 2009-2011, Mr. Hrkac
served as Europe, Middle East & Africa president of Boston
Scientific where he was responsible for close to $2 billion of
sales. From 2005-2009, Mr. Hrkac was an executive of Sorin Group
CRM, Paris, France. And, from November 1990-April 2005 he lived in
6 different countries working as an executive for Johnson &
Johnson including Biosense Webster, a Johnson & Johnson company
having laid the groundwork strategically for the most successful
J&J division of the last 20 years with sales growing from a few
hundred million dollars to several billion dollars. Mr. Hrkac
holds an Honors Bachelor of Business Administration from the
Wilfrid Laurier University, Waterloo, Ontario Canada. Mr. Hrkac
brings extensive expertise in global marketing and strategic
business development, making him a valuable resource for our
Board.
Director #4, Steven E. Abelman
Mr. Steven E. Abelman has more than 30 years of commercial
litigation experience and currently serves as a shareholder for
Brownstein Hyatt Farber Schreck in Denver, CO. Mr. Abelman is
a trusted advisor and trial counsel to banks, lending institutions
and a variety of organizations and recognized by his peers for his
expertise at the intersection of litigation and transactional law.
Yearly recognized as a top bankruptcy attorney, Mr. Abelman
has been a frequent lecturer on bankruptcy and creditors’ rights
topics, and combines sage advice, objective counsel with effective
advocacy. The combination of over 30 years of handling loan
workouts and dissolutions provide him with unique transactional
aptitude for a commercial litigator. He serves as a trusted advisor
and trial counsel to many banks and other lending institutions, as
well as to businesses of various sizes.
Mr. Abelman is especially known for his success in representing
creditors in large commercial bankruptcy cases, receiverships, and
foreclosures, defending banks in lender liability cases, and
representing both debtors and creditors in workout scenarios and
distressed asset sales. He also represents parties regarding UCC
matters and equipment lessors. Mr. Abelman graduated with a J.D. in
1984 from Whittier College Law School and a B.S. in 1979 from
University of Chicago; was admitted to the U.S. Supreme Court, U.S.
District Court, District of Colorado in 1984. Mr. Abelman’s
extensive legal experience makes him an asset to the Board.
Director #5, Donald F. Browne, C.P.A.
Mr. Donald F. Browne, C.P.A. is a graduate of La Salle College,
1972, with a B.S. in accounting and later became licensed as a
certified public accountant from the state of New Jersey in
1980. Mr. Browne’s career has included being employed as a
divisional controller of Caddy Corporation of America and a
controller for Full Line Foods, Inc.
In 1990, Mr. Browne’s career then transitioned to public
accounting, a field in which he launched his own firm (which he
continues to run and operate). Mr. Browne specializes in
business accounting, including financial and tax reporting for
businesses of several different industries and professions;
concentrations in federal and state tax audits. Mr. Browne’s tax
and financial expertise makes him a valuable asset to our
Board.
About BioSig Technologies, Inc. (NASDAQ: BSGM)
BioSig Technologies is a medical technology company focused on
deciphering the body’s electrical signals, starting with heart
rhythms. By leveraging a first of its kind combination of hardware
and software, we deliver unprecedented cardiac signal clarity,
ending the reliance on ‘mixed signals’ and ‘reading between the
lines.’ Our platform technology is addressing some of healthcare’s
biggest challenges—saving time, saving costs, and saving lives.
The Company’s product, the PURE EP™ Platform, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform highly targeted
cardiac ablation procedures with increased procedural efficiency
and efficacy.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of
future performance, are based on certain assumptions, and are
subject to various known and unknown risks and uncertainties, many
of which are beyond the Company's control, and cannot be predicted
or quantified and consequently, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with (i) BioSig’s
ability to regain compliance with and meet the continued listing
requirements of the Nasdaq Capital Market to maintain listing of
its common stock; (ii) our cost reduction plan and associated
workforce reduction or other cost-saving measures not reaching the
targeted reduction of cash burn by 50%; (iii) the geographic,
social, and economic impact of pandemics or worldwide health issues
on BioSig’s ability to conduct its business and raise capital in
the future when needed; (iv) BioSig’s inability to manufacture its
products and product candidates on a commercial scale on its own,
or in collaboration with third parties; (v) difficulties in
obtaining financing on commercially reasonable terms; (vi) changes
in the size and nature of BioSig’s competition; (vii) loss of one
or more key executives or scientists; and (viii) difficulties in
securing regulatory approval to market BioSig’s products and
product candidates. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause BioSig’s actual results to differ from those contained in
forward-looking statements, see BioSig’s filings with the
Securities and Exchange Commission (“SEC”), including the section
titled “Risk Factors” in BioSig’s Annual Report on Form 10-K, filed
with the SEC on April 16, 2024. Investors and security holders are
urged to read these documents free of charge on the SEC's website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise, except as
required by law.
Todd Adler
BioSig Technologies, Inc.
Investor Relations
55 Greens Farms Westport, CT 06880
Email: tadler@biosigtech.com
Tel. 203-409-5444, x104
Anthony Amato, Chief Executive Officer
Email: aamato@biosigtech.com
Tel. 203-409-5444 ext. 102
BioSig Technologies (NASDAQ:BSGM)
過去 株価チャート
から 4 2024 まで 5 2024
BioSig Technologies (NASDAQ:BSGM)
過去 株価チャート
から 5 2023 まで 5 2024